Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)

Trial Profile

Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2015

At a glance

  • Drugs Rilonacept (Primary)
  • Indications Juvenile rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RAPPORT
  • Most Recent Events

    • 16 May 2014 Results at week 12 and week 24 published in the Arthritis and Rheumatology.
    • 30 Oct 2013 Primary endpoint 'Time-to-clinical-response' has been met according to results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 30 Oct 2013 Status changed from active, no longer recruiting to completed as reported at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top